Alterity Therapeutics Inc. (NASDAQ: ATHE) stock gained by 7.91% at last close whereas the ATHE stock price declines by 3.33% in the pre-market trading session. Alterity Therapeutics is a clinical-stage biotech firm devoted to a better future for those suffering from neurodegenerative disorders. ATH434 which is ATHE’s main asset, has the potential to treat a variety of Parkinson’s diseases.
>> 7 Top Picks for the Post-Pandemic Economy <<
What is happening?
The results of a research indicating that ATH434 decreases –synuclein associated neurodegeneration in a well-established mouse model of Multiple System Atrophy have been published in Movement Disorders, the authorized journal of the International Parkinson and Movement Disorder Society.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Professor Nadia Stefanova directed the research at the Facility for Translational Neurodegeneration Research, Department of Neurology, the Medical University of Innsbruck in Austria, a leading animal research laboratory in MSA
The preclinical investigation found that ATH434 therapy enhanced motor function and was neuroprotective, fully supporting and expanding prior findings from another university lab, together in the same MSA model and in animal models of Parkinson’s disease. ATH434 decreased both the accumulated form of –synuclein and the so-called toxic oligomeric form in preserved neurons, which is considered to be the cause of illness propagating to other neurons. ATH434 also decreased brain iron in regions of disease, which is consistent with its mode of action.
Furthermore,
Aside from these findings, the study also demonstrated for the first time that ATH434 maintained neurons in the striatum, a brain area known to be damaged in MSA patients. Importantly, ATH434 enhanced performance on a variety of motor tests, including a favorable effect on the balance-testing “challenging beam” task. This last result is particularly important for MSA patients, as the poor balance is a primary source of impairment.
